Spots Global Cancer Trial Database for A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Official Title: A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Study ID: NCT06120075
Conditions
Study Description
Brief Summary: The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
START MIdwest, Grand Rapids, Michigan, United States
Icahn School of Medicine at Mount Sinai/ The Tisch Cancer Cente, New York, New York, United States
Mary Crowley, Dallas, Texas, United States
START - South Texas Accelerated Research Theraputics, LLC., San Antonio, Texas, United States
START Mountain Region, West Valley City, Utah, United States
Next Oncology Virginia, Fairfax, Virginia, United States
Contact Details
Name: Medical Director
Affiliation: Arcus Biosciences
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
